CureVac (CVAC)
(Delayed Data from NSDQ)
$5.41 USD
-0.04 (-0.73%)
Updated Oct 6, 2025 04:00 PM ET
After-Market: $5.42 +0.01 (0.18%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CVAC 5.41 -0.04(-0.73%)
Will CVAC be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CVAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CVAC
Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Kamada (KMDA) Q2 Earnings Top Estimates
CVAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
Other News for CVAC
Is CVAC set to rally? Crossed Above 50 Day Moving Average shows up after gaining 1.11%
50 Day Moving Average Resistance appears for CVAC after 0.37% move
CVAC forms Directional Movement Crossover Bullish on October 1
Crossed Above 20 Day Moving Average appears for CVAC after 0.75% move
CureVac: The Hidden Value Of The mRNA Wallet